1. BRCA1 and BRCA2 screening of nine Chilean founder mutations through allelic-discrimination and real-time PCR in breast/ovarian cancer patients
   Carolina Alvarez et al, 2022, Molecular Biology Reports CrossRef
2. Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12
   Dolores Gallardo-Rincón et al, 2022, Frontiers in Genetics CrossRef